Dr Johnny E Camargo, MD | |
101 E Matthews St Ste 400, Matthews, NC 28105-5373 | |
(980) 339-7442 | |
(980) 339-5925 |
Full Name | Dr Johnny E Camargo |
---|---|
Gender | Male |
Speciality | Internal Medicine |
Experience | 44 Years |
Location | 101 E Matthews St Ste 400, Matthews, North Carolina |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1134161714 | NPI | - | NPPES |
89-20866 | Medicaid | NC |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207R00000X | Internal Medicine | 34264 (North Carolina) | Primary |
Entity Name | Rockingham Medical Clinic, P.c. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1124309463 PECOS PAC ID: 2567633696 Enrollment ID: O20110922000183 |
News Archive
Melanomas caused by sun exposure have been matched with targeted treatments and immunotherapies, in many cases dramatically extending patients' lives. However, there are other kinds of melanoma not related to sun exposure and because they are caused by different genetic changes, they are not susceptible to the same targeted treatments.
Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, today announced that it has received orphan drug designation in the European Union for unoprostone isopropyl for the treatment of retinitis pigmentosa (RP). RP is a genetic disease characterized by progressive, irreversible vision loss and decreasing visual acuity, and there are no drugs or therapeutic procedures currently approved for the treatment of RP today.
Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).
According to British scientists smokers who suddenly decide to quit immediately, without making plans about how or when, are far more likely to succeed.
FDA officials on Tuesday said the agency would need at least $225 million in additional funding annually, along with other authoritative powers, to adequately inspect the safety of imported drug products, the Baltimore Sun reports.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Johnny E Camargo, MD 101 E Matthews St Ste 400, Matthews, NC 28105-5373 Ph: (980) 339-7442 | Dr Johnny E Camargo, MD 101 E Matthews St Ste 400, Matthews, NC 28105-5373 Ph: (980) 339-7442 |
News Archive
Melanomas caused by sun exposure have been matched with targeted treatments and immunotherapies, in many cases dramatically extending patients' lives. However, there are other kinds of melanoma not related to sun exposure and because they are caused by different genetic changes, they are not susceptible to the same targeted treatments.
Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, today announced that it has received orphan drug designation in the European Union for unoprostone isopropyl for the treatment of retinitis pigmentosa (RP). RP is a genetic disease characterized by progressive, irreversible vision loss and decreasing visual acuity, and there are no drugs or therapeutic procedures currently approved for the treatment of RP today.
Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).
According to British scientists smokers who suddenly decide to quit immediately, without making plans about how or when, are far more likely to succeed.
FDA officials on Tuesday said the agency would need at least $225 million in additional funding annually, along with other authoritative powers, to adequately inspect the safety of imported drug products, the Baltimore Sun reports.
› Verified 6 days ago
Vidyasagargoud Marupakula, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Healing Way, Matthews, NC 28104 Phone: 980-993-2240 | |
Zelalem Atakilt Gebreananya, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1500 Matthews Township Pkwy, Matthews, NC 28105 Phone: 704-384-9740 Fax: 704-384-9565 | |
Nusrat Ahmad Chaudhary, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1700 Matthews Township Pkwy, Matthews, NC 28105 Phone: 704-841-8151 | |
Dr. Henry D Cremisi, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 1500 Matthews Township Pkwy, Matthews, NC 28105 Phone: 704-384-5416 Fax: 704-384-5992 | |
Dr. Kevin M. Rudisel, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1500 Matthews Township Pkwy, Matthews, NC 28105 Phone: 704-384-5420 Fax: 704-384-5424 | |
Dr. Abdul Karim Garuba, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 9705 Northeast Pkwy Ste 400, Matthews, NC 28105 Phone: 704-844-8971 Fax: 704-844-8972 | |
Dr. Keithe Saclayan Shensky, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1700 Matthews Township Pkwy, Matthews, NC 28105 Phone: 704-841-8151 Fax: 704-841-9228 |